The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Guardant Health
Speakers' Bureau - Guardant Health; NanoString Technologies; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
 
Deborah Blythe Doroshow
Consulting or Advisory Role - Boehringer Ingelheim; Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Wei Wei
No Relationships to Disclose
 
Jon Zugazagoitia
No Relationships to Disclose
 
Charles Jack Robbins
No Relationships to Disclose
 
Swati Gupta
Employment - H3 Biomedicine
 
Blythe J.S. Adamson
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
Research Funding - Flatiron Health
Patents, Royalties, Other Intellectual Property - Flatiron Health
 
David L. Rimm
Stock and Other Ownership Interests - Pixel Gear
Honoraria - Amgen; Bristol-Myers Squibb; Ventana Medical Systems
Consulting or Advisory Role - Agendia; AstraZeneca; Bristol-Myers Squibb; Cell Signaling Technology; Cepheid; Daiichi Sankyo; GlaxoSmithKline; Konica Minolta; Merck; NanoString Technologies; NextCure; PAIGE.AI; Perkin Elmer; Roche; Sanofi; Ultivue
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Cepheid (Inst); Konica Minolta (Inst); Lilly (Inst); NanoString Technologies (Inst); Navigate Biopharma (Inst); NextCure (Inst); Perkin Elmer (Inst); Ultivue (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Travel, Accommodations, Expenses - Bristol-Myers Squibb; NextCure; Ventana Medical Systems